Cipla, India’s second-largest drug maker by market share has formed an India-specific strategic partnership with MSD, one of the world’s leading players in HIV innovative treatment. Within the scope of the partnership, Cipla will have a non-exclusive license to market, promote and distribute MSD’s raltegravir 400mg tablet, under a different brand name in India.For more information ✆ - 0731-6642300 or Visit https://www.epicresearch.co/
No comments:
Post a Comment